In addition, 618 participants (4.54%) were ALT> 40 U/L or AST > 40 U/L and AST/ALT> 2, 3726 participants (27.40%) were GGT > 55 U/L, 270 participants (1.99%) were MCV > 96 fL, 5697 participants (41.89%) had liver steatosis (Fibrotouch DBM ≥ 240 db/m), 376 participants (2.76%) had liver fibrosis (Fibrotouch LSM ≥ 12.96 Kpa), and 974 participants were diagnosed with ALD. This evidence concerns the gene GPT and Hepatic fibrosis.